Tier 1 — highest

Low-Dose Daily Intake of Vitamin K(2) (Menaquinone-7) Improves Osteocalcin γ-Carboxylation: A Double-Blind, Randomized Controlled Trials

Naoko Inaba, Toshiro Sato, Takatoshi Yamashita
Journal of nutritional science and vitaminology 2015 61(6):471-80

Bibliography

PubMed
PMID 26875489
DOI
10.3177/jnsv.61.471
Funding
Funding is not specified in the indexed abstract or accessible funding metadata. Consult the original publication for the declaration.
Competing interests
A competing-interest declaration is not available in the indexed abstract or accessible disclosure metadata.

Study snapshot

DesignRandomized controlled clinical trial
ModelHuman participants
Sample60 women in a dose-finding trial and 120 adults in a second randomized trial
InterventionMK-7 0–200 μg/day in study 1; 100 μg/day or placebo in study 2
Duration4 weeks and 12 weeks, respectively
EndpointsCarboxylated and undercarboxylated osteocalcin

What the study showed, in plain terms

This publication examines carboxylated and undercarboxylated osteocalcin. Study population or evidence base: 60 women in a dose-finding trial and 120 adults in a second randomized trial. Intervention or exposure: MK-7 0–200 μg/day in study 1; 100 μg/day or placebo in study 2.

Key findings

MK-7 showed a dose-related improvement in osteocalcin carboxylation; daily doses of 100 μg or more produced significant effects in these studies.

What this study can and cannot tell us

Two short biomarker trials are reported in one paper. The findings do not establish effects on bone density, fractures or cardiovascular events.

Related papers in the corpus

Tier 1
Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women
M H J Knapen et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013
Tier 1
The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial
S H Rønn et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021
Tier 1
Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women
Sofie Hertz Rønn et al. · European journal of endocrinology · 2016
Tier 1
Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial
N Emaus et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2010
Tier 1
Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study
Yingfeng Zhang et al. · Calcified tissue international · 2020
Tier 1
Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women
M H J Knapen et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2007

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Biohack Blueprint Research